01—Abstract
Summary
Summary of the 10-Q filed July 25, 2024. Cited figures are marked; the original filing is the authoritative source.
West Pharmaceutical Services, Inc. reported second-quarter 2024 net sales of $702.1 milliona, down from $753.8 million in the prior-year quarter, with net income of $111.3 million versus $155.1 million and diluted EPS of $1.51 versus $2.06.
For the six months ended June 30, 2024, net sales were $1,397.5 millionb (compared with $1,470.4 million) and net income was $226.6 million (compared with $295.1 million). Consolidated operating profit fell to $126.2 million for the quarter from $182.5 million, and gross profit declined to $230.0 million from $291.4 million, with the filing citing lower plant absorption from reduced customer demand and an unfavorable product mix in Proprietary Products. The decline was attributed in part to customers' inventory management, which reduced sales of certain high-value product offerings, including Westar, Daikyo Crystal Zenith and FluroTec products.
Cash and cash equivalents fell to $446.2 millionc at June 30, 2024 from $853.9 million at December 31, 2023, reflecting $454.1 million of share repurchases and $190.8 million of capital expenditures in the six months, partly offset by $283.2 million of operating cash flow. Working capital decreased to $849.3 million from $1,264.6 million. The company stated it was in compliance with all debt covenants and that its $500.0 million Credit Facility had $497.6 million of available borrowing capacity.
After the quarter end, on July 2, 2024, West entered into a Third Amendment to its Credit Facility that established a $130.0 milliond New Term Loan maturing July 2, 2027. Proceeds, together with cash on hand, were used to repay the $79.9 million term loan and $53.0 million of Series B Senior Notes due July 5, 2024.
02—Key points
Key Highlights
- Net sales declined 6.9% to $702.1 million in Q2 2024 from $753.8 million, with Proprietary Products sales down 9.4% and Contract-Manufactured Products up 4.9%.
- Gross profit fell to $230.0 million from $291.4 million, and consolidated gross profit margin was 32.8% versus 38.7% a year earlier.
- Operating profit decreased to $126.2 million from $182.5 million, a 30.8% decline, and diluted EPS was $1.51 compared with $2.06.
- Share repurchases totaled $454.1 million in the first six months of 2024, and the company bought 1,239,015 shares at an average price of $366.53.
- Cash and cash equivalents decreased to $446.2 million from $853.9 million at year-end 2023, and working capital fell to $849.3 million from $1,264.6 million.
- Capital expenditures were $190.8 million in the first six months, which the company attributed to additional manufacturing capacity to meet customer demand.
- Subsequent to quarter end, the company entered a $130.0 million New Term Loan maturing July 2, 2027, used to repay the $79.9 million term loan and $53.0 million of Series B notes.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q2 FY2024, West Pharmaceutical Services kept $0.16.
- Revenue$702.1M100.0%
- Cost of revenue−$472.1M67.2%
- Gross profit$230.0M32.8%
- Operating costs−$103.8M14.8%
- Operating income$126.2M18.0%
- Interest, other & tax−$14.9M2.1%
- Net income$111.3M15.9%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2024filed July 25, 2024Financial Statements
Q2 FY2024 against Q2 FY2023
| Line item | Q2 FY2024Q2 FY2023 | Change |
|---|---|---|
| Revenue | $702.10M$753.80M | −6.9% |
| Cost of Revenue | $472.10M$462.40M | +2.1% |
| Gross Profit | $230.00M$291.40M | −21.1% |
| R&D Expenses | $17.50M$16.50M | +6.1% |
| SG&A Expenses | $83.00M$88.40M | −6.1% |
| Operating Income | $126.20M$182.50M | −30.8% |
| Net Income | $111.30M$155.10M | −28.2% |
| EPS (Basic) | $1.52$2.08 | −26.9% |
| EPS (Diluted) | $1.51$2.06 | −26.7% |
| Shares Outstanding (Basic) | 73.00M74.30M | −1.7% |
| Shares Outstanding (Diluted) | 73.70M75.40M | −2.3% |
05—Questions
Frequently Asked Questions
Why did West Pharmaceutical's sales and profits decline in the second quarter of 2024?
Management attributed the decline in Proprietary Products to customer inventory management, which reduced sales of certain high-value product offerings such as Westar components, Daikyo Crystal Zenith and FluroTec products. Lower plant absorption from reduced customer demand and an unfavorable product mix also reduced gross profit margin, partly offset by increased sales prices.
How much cash did West Pharmaceutical return to shareholders in the first half of 2024?
The company purchased $454.1 million of common stock under its share repurchase program during the six months ended June 30, 2024. It also paid dividends of $29.3 million, declared at $0.20 per share in each of the first two quarters of 2024.
What is the status of West Pharmaceutical's debt and liquidity?
Total debt was $205.8 million at June 30, 2024, and the company had no outstanding borrowings under its $500.0 million Credit Facility, with $497.6 million of borrowing capacity available. The company stated it was in compliance with all debt covenants and believed its cash, operating cash flow and Credit Facility would be adequate for foreseeable liquidity needs.
What changes to the company's debt occurred after the quarter ended?
On July 2, 2024, West entered into a Third Amendment to its Credit Facility Agreement that established a $130.0 million New Term Loan maturing July 2, 2027, with no scheduled amortization before maturity. Proceeds and cash on hand were used to repay the $79.9 million term loan and $53.0 million of 3.82% Series B Senior Notes due July 5, 2024.
Is the company's tax rate changing, and what drove the decrease in the second quarter?
The effective tax rate was 17.0% for the three months ended June 30, 2024, compared with 18.8% a year earlier. The company said the decrease was primarily due to a shift in the forecasted geographic earnings mix, partly offset by a smaller tax benefit related to stock-based compensation.
06—Continue